This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Publications

EAS Newsletter September 15, 2020

Tuesday 15 September 2020   (0 Comments)
Share |
EAS Society & Governance

EAS Society election 2020: Presentation of candidates - members of the Executive Committee

This is an important time in the life of the Society. The new appointments to the Society leadership will have a major influence on the policies and activities of the EAS for years to come. We encourage all eligible members to vote, so the elected leadership will truly represent the values of our members.Voting is open September 01-30.The election is for the Officer positions of Vice President, Treasurer-Elect & Secretary, as well as three Executive Committee Member positions. Voting is via a website-based ballot of Society members, according to the Society's bylaws.We are grateful to the candidates for contributing to the life of the Society by standing in this year's elections.

EAS Executive Committee member candidates

The following ten candidates have been selected by the Election Committee to stand in the election for three (3) vacant positions as an Executive Committee member.

Prof George  Prof Holven Prof Roeters
van Lennep
 Prof Civeira
 Prof März
Prof Plat  Prof Romeo Prof Santulli Prof Zambon  Prof Öörni

 To EAS Election 2020 >> 

EAS Publications

Featured Commentary: DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe

Results of DA VINCI, an EU Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care, underline the need for combination therapy for patients at highest risk and in whom the lowest LDL-C goals are recommended.

What guidelines recommend and the clinical reality for lipid management in routine practice differ. This issue was previously highlighted by the EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) study in secondary prevention patients. This survey showed that 71% of these very high-risk patients had low-density lipoprotein cholesterol (LDL-C) values below the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guideline goals set in 2016. Lack of awareness of guideline recommendations was a potential factor contributing to suboptimal lipid management.

In 2019, the ESC/EAS updated guidelines for lipid management. This revision took account of evidence that lowering LDL-C levels below the 2016 ESC/EAS goals improves clinical benefit, based on landmark studies with ezetimibe (IMPROVE-IT) and PCSK9 monoclonal antibody therapy (FOURIER and ODYSSEY OUTCOMES). Consequently, LDL-C goals were lowered for moderate to very high cardiovascular risk patients. Additionally, in high and very high-risk categories, at least 50% reduction in LDL-C levels from baseline, a proxy for the use of high-intensity of statin, was also added.

One year on, it is important to review how these revised guidelines might be implemented in routine practice. This was the aim of the DA VINCI study (EU Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care)


In case you missed it...
EAS webinar

Lipids & atherosclerosis in Covid era - available on demand

We would like to thank our chair and distinguished speakers for a most informative and timely webinar! Thanks also to the participants for joining the discussion.
If you were not able to join, the lectures and Q&A are available to watch again.

To the webinar Lipids & atherosclerosis in Covid era>>


FH week September 21-25

With our 2020 FH Week campaign we update on the FHSC’s activities and progress, as well as joining with the FH community to raise awareness of the condition on FH Awareness day, September 24.

During FH Week, a series of newsletters are going out to EAS members and stakeholders and FH related information is published daily in our social media channels.

Anitschkow 2021

Call for nominations

It is time once again to welcome nominations for the Society's Anitschkow Prize. This prestigious Prize, awarded annually, recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances.

EAS individual members are welcome to nominate their distinguished colleagues before the closing date of Monday 12 October, 2020

To Anitschkow Nomination >>


Membership Software Powered by YourMembership  ::  Legal